glp 1 agonist vision loss Ozempic Lawsuit [2026 Update] The Impact of GLP-1 Receptor
Description
Patients taking GLP-1 receptor agonists had a 1.15 HR of developing NAION compared to control
![glp 1 agonist vision loss Ozempic Lawsuit [2026 Update] The Impact of GLP-1 Receptor](https://res.cloudinary.com/broadcastmed/image/fetch/q_auto,f_auto,dpr_auto/https://www.glaucomaphysician.net/media/30hgcds4/pg15_fig1_sept25.jpg)
Nat Rev Dis Primers 1:15018
![glp 1 agonist vision loss Ozempic Lawsuit [2026 Update] The Impact of GLP-1 Receptor](https://www.newswise.com/legacy/image.php?image=/images/uploads/2026/07/14/6a565cf0b708d_GLP1.png)
GLP-1 receptor agonists (GLP-1 RAs) have transformed obesity and Type 2 diabetes mellitus (T2DM) management, offering benefits in glucose regulation, weight loss, and cardiometabolic health (6)
Tirzepatide (Mounjaro) has shown even stronger weight loss results, with an average weight loss of 15-20% in recent trials
![glp 1 agonist vision loss Ozempic Lawsuit [2026 Update] The Impact of GLP-1 Receptor](https://assets.newsweek.com/wp-content/uploads/2026/07/GLP-1-medications-linked-to-risk-of-sudden-vision-loss.png?w=1600&h=900&q=88)
Bioinformatics 38 , 34773480 (2022)
![glp 1 agonist vision loss Ozempic Lawsuit [2026 Update] The Impact of GLP-1 Receptor](https://res.cloudinary.com/broadcastmed/image/fetch/q_auto,c_fill,g_faces:center,f_auto/https://vision-umbraco.euwest01.umbraco.io/media/ezumjwoe/0426-203-wegovy-and-possible-vision-risk.png)
"Wegovy (semaglutide) injection, for subcutaneous use